tiprankstipranks
Trending News
More News >

Mineralys Therapeutics Unveils Promising Trial Results for Lorundrostat

Story Highlights
  • Mineralys Therapeutics announced results from the Advance-HTN trial on March 29, 2025.
  • Lorundrostat showed significant blood pressure reductions and a favorable safety profile.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Mineralys Therapeutics Unveils Promising Trial Results for Lorundrostat

Confident Investing Starts Here:

Mineralys Therapeutics, Inc. ( (MLYS) ) has shared an announcement.

On March 29, 2025, Mineralys Therapeutics announced detailed results from the Advance-HTN pivotal trial of lorundrostat for uncontrolled and resistant hypertension. The trial demonstrated significant blood pressure reductions and a favorable safety profile, underscoring lorundrostat’s potential as a best-in-class treatment for high-risk patients. The results were presented at the American College of Cardiology’s Annual Scientific Session & Expo, highlighting lorundrostat’s clinical utility across diverse care settings and its potential impact on hypertension care.

More about Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines targeting hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and other diseases driven by dysregulated aldosterone.

YTD Price Performance: 19.67%

Average Trading Volume: 897,346

Technical Sentiment Signal: Strong Sell

Current Market Cap: $920.4M

Learn more about MLYS stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App